As a pioneer of nicotinamide adenine
dinucleotide (NAD+) and healthy aging research, ChromaDex aims to
raise awareness amongst industry leaders
ChromaDex Corp. (NASDAQ:CDXC) today announced that members of
its team, a Scientific Advisory Board member and two ChromaDex
External Research Program (CERP™) investigators, will be presenting
at several key scientific conferences including the American
Society for Nutrition’s (ASN) Nutrition 2022, the International
Society of Sports Nutrition (ISSN) annual meeting, and Federation
of American Societies for Experimental Biology (FASEB), The NAD+
Metabolism and Signaling Conference. CERP™ is a pioneering program
in nicotinamide adenine dinucleotide (NAD+) research and healthy
aging and most recently celebrated over 250 material transfer
agreements with over 235 independent scientists, doctors, and
investigators across 182 institutions and 33 countries. Many of the
agreements were developed to study Niagen®, ChromaDex’s proprietary
nicotinamide riboside (NR) ingredient, an efficient precursor for
the essential cellular coenzyme, NAD+. ChromaDex aims to raise
awareness of this research at ASN, ISSN and FASEB.
Below is an overview of how ChromaDex will be participating in
each event.
American Society for Nutrition, Nutrition 2022, June 14-16,
2022 (Virtual):
ChromaDex and co-sponsor Balchem are sponsoring the Satellite
Program, Exploring the Role of Selected Vitamins and Essential
Nutrients in Cognition: Impact of Supplementation on
Neurodegeneration, which takes place today on June 15 from
12:00-1:30pm EDT. The discussion will feature two CERP™
investigators, Dr. Charalampos Tzoulis (Clinical Neurologist and
Professor of Neurology & Neurogenetics, Haukeland University
Hospital, University of Bergen, Norway), and Dr. Vilhelm Bohr
(Retired Laboratory Chief, Laboratory of Molecular Gerontology,
National Institutes on Aging, National Institutes of Health in
Baltimore, Maryland) alongside Dr. Jim Ray (Executive Director
Neuroscience, The Neurodegeneration Consortium, MD Anderson Cancer
Center in Houston, Texas).
In addition, three ChromaDex employees will be presenting at the
conference: Rebecca Idoine, CERP™ Specialist at ChromaDex, will
present in the session Impact of Boosting NAD+ on Immune Function:
Results from Nicotinamide Riboside Preclinical Studies (Oral Talk);
Jun Kwon, a CERP™ Scientist at ChromaDex, will speak at The
Clinical Effects of Nicotinamide Riboside on Inflammatory
Parameters (Poster); and Dr. Yasmeen Nkrumah-Elie, Global Director
of External Research for ChromaDex, will speak at Nicotinamide
Riboside Supports Brain Health: Assessing the Evidence.
International Society of Sports Nutrition (ISSN), June 16 –
18, 2022, (Fort Lauderdale Beach, Florida):
ChromaDex’s Mona Rosene, MS, RD and Global Director of
Scientific Affairs, will be presenting on NAD+, Muscle, and
Athletic Performance: Current Research and Future Needs. Her
presentation will provide an overview of clinical research and
future research needs to better understand the role of NAD+ and
NAD+ precursors in muscle and exercise performance.
Federation of American Societies for Experimental Biology:
The NAD+ Metabolism and Signaling Conference, June 26
– 30, 2022 (Steamboat Springs, Colorado):
ChromaDex will engage with scientists from multiple disciplines
to share the latest findings in NAD+ metabolism and signaling
related to human health, disease, and medicine. ChromaDex has two
abstract submissions accepted, one of which Dr. Yasmeen
Nkrumah-Elie, Global Director of External Research for ChromaDex,
will be presenting as a short talk titled, “Effect of nicotinamide
riboside supplementation on cognition and related outcomes in a
group of healthy older adults.” Her talk will be held during
Session 9: NAD+ Metabolism and Interventions in Aging and Disease,
on Thursday, June 30, along with Dr. Charles Brenner, ChromaDex’s
Chief Scientific Advisor on the Scientific Advisory Board, who will
be discussing nicotinamide riboside in physiology and
therapeutics.
The second abstract, authored by Yusrah Istiaq, Scientific
Affairs Manager at ChromaDex, will be presented as a poster by Aron
Erickson, Vice President of Research and Development at ChromaDex,
titled, “Mean Baseline NAD+ In Human Biofluids and Tissues: An
Evaluation of the Clinical Evidence.”
Lastly, ChromaDex is sponsoring a social hour event on Tuesday,
June 28, between 4:00-6:00pm MT, where attendees will enjoy
appetizers and a short presentation from Dr. Nkrumah-Elie.
For additional information on ChromaDex, visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to increasing awareness of
the Company’s research. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential," "possible," "probable," "believes," "seeks," "may,"
"will," "should," "could" or the negative of such terms or other
similar expressions. Risks that contribute to the uncertain nature
of these forward-looking statements include the impact of the
COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2021, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220615005196/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024